Drug Trial Radar · NCT07405606
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Mar 23, 2026
Primary completion
Mar 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Centre for Addiction and Mental HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to determine the safety and efficacy of psilocybin assisted Therapy (PAT) in individuals with comorbid Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD). The main question it aims to answer is: \- What is the feasibility and safety of administering PAT in adults with MDD-AUD by evaluating recruitment, retention, tolerability, and safety? Researchers will compare the psilocybin (25 mg) and placebo groups to see if there are any significant differences in frequency of dropouts or serious adverse events. Participants will: * be randomized to receive either psilocybin (25 mg) or placebo * visit the site (in-person and remotely) for a total of 14 times to complete study tasks * receive psilocybin-assisted therapy (PAT) at five various timepoints
Conditions
- Major Depressive Disorder (MDD)
- Alcohol Use Disorder (AUD)
Interventions
Psilocybin 25 mgDrug
Participants will orally consume Psilocybin (25 mg) with water.
PlaceboDrug
Participants will orally consume placebo matching the intervention with water.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AdherenceTime frame: Week 2 (Visit 4)
- Montgomery-Asberg Depression Rating Scale (MADRS)Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
- Hamilton Depression Rating Scale (HAMD-17)Time frame: 4-week post dose; week 26.
- Quick Inventory of Depressive Symptomatology - Self Report (QUIDS-SR)Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
- Alcohol Timeline Followback (TLFB)Time frame: Baseline; week 2 (visit 3); 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
- Clinical Institute Withdrawal Assessment (CIWA)Time frame: Baseline; week 2 (visit 3); week 2 (visit 4); 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
- Prediction of Alcohol Withdrawal Severity Scale (PAWSS)Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
- Penn Alcohol Craving Scale (PACS)Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
- Addiction Severity Index (ASI)Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre for Addiction and Mental Health
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.